A significantly lower risk of cardiovascular events was observed in SU users than in nonusers in the female and male sex, age 60 to 80 years, no obesity, no smoking, CCI ≥ 1, DCSI ≥ 2, OAD numbers = 2–3, and insulin use (Table S3). The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.